Back to top
more

Allergan plc (AGN)

(Delayed Data from NYSE)

$145.81 USD

145.81
1,518,334

+1.56 (1.08%)

Updated May 3, 2019 04:01 PM ET

After-Market: $145.88 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[AGN]

Reports for Purchase

Showing records 101 - 120 ( 226 total )

Industry: Medical - Generic Drugs

Record: 101

07/02/2018

Company Report

Pages: 10

Price: 24.95

Industry: Medical - Generic Drugs

Record: 102

06/19/2018

Company Report

Pages: 10

Price: 24.95

Industry: Medical - Generic Drugs

Record: 103

06/01/2018

Company Report

Pages: 2

Will Selling Women?s Health and Antibiotics be Enough? - Buy

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 104

05/18/2018

Company Report

Pages: 10

Price: 24.95

Industry: Medical - Generic Drugs

Record: 105

05/01/2018

Company Report

Pages: 2

Breaking Up Is Hard To Do - Buy

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 106

04/20/2018

Company Report

Pages: 2

Shire, Shire, Stock on Fire - Buy

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 107

04/16/2018

Company Report

Pages: 9

Price: 24.95

Industry: Medical - Generic Drugs

Record: 108

03/13/2018

Company Report

Pages: 9

Price: 24.95

Industry: Medical - Generic Drugs

Record: 109

02/16/2018

Industry Report

Pages: 15

Recent Drug Launch Weekly Retail Sales Tracker - Week Ending February 9

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 110

02/12/2018

Company Report

Pages: 10

Price: 24.95

Industry: Medical - Generic Drugs

Record: 111

02/07/2018

Company Report

Pages: 2

Q4 Results, Ubrogepant Clears First Hurdle - Buy

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 112

01/19/2018

Company Report

Pages: 13

Best Idea for 2018 - Buy

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 113

01/19/2018

Company Report

Pages: 9

Price: 24.95

Industry: Medical - Generic Drugs

Record: 114

01/12/2018

Industry Report

Pages: 4

NASH Weekly Newsletter: NASH News Flow From JP Morgan Healthcare Conference

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 115

01/10/2018

Company Report

Pages: 2

Preliminary 2018 Outlook, Tax Act Update - Buy

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 116

01/02/2018

Company Report

Pages: 8

Price: 24.95

Industry: Medical - Generic Drugs

Record: 117

12/08/2017

Company Report

Pages: 9

Price: 24.95

Industry: Medical - Generic Drugs

Record: 118

12/06/2017

Company Report

Pages: 2

Turn That Revance Frown Upside Down: Buy on Weakness - Buy

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 119

12/04/2017

Daily Note

Pages: 60

2018 Top Stock Picks

Provider: G.RESEARCH, LLC

Price: 100.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 120

11/30/2017

Company Report

Pages: 2

Not Afraid to Have a Little Work Done - Buy

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party
// eof